Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Barzolvolimab (Primary)
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Therapeutic Use
Acronyms ColdU
Sponsors Celldex Therapeutics Inc

Most Recent Events

06 Aug 2026 Results presented in the Celldex Therapeutics Inc media release.
10 Jun 2026 According to a Celldex Therapeutics Inc media release, data from this study will be presented at European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
27 Mar 2026 Results presented in the Celldex Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com